Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-allo10 for GvHD Prevention in Mismatched HSCT
NCT03198234Phase 1Terminated
- Start
- Aug 2017
- Primary completion
- Nov 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of T-allo10 in graft-versus-host disease (GVHD) (3 cohorts). Primary endpoints: Treatment Emergent Adverse Events, Stem Cell Engraftment and 1 more. Started Aug 2017; status: terminated.
02
Drugs
T-allo10
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03198234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198234.